Summary
Regeneron Pharmaceuticals, Inc. (REGN) has filed a Form 8-K to disclose anticipated financial results for the first quarter of 2026. The company expects to record an acquired in-process research and development (IPR&D) charge of approximately $102 million on a pre-tax basis. This charge is primarily associated with equity securities purchased and payments made under collaboration and licensing agreements. The most significant impact for investors is the expected negative effect of this IPR&D charge on both GAAP and non-GAAP net income per diluted share, estimated at $0.81 for the first quarter of 2026. It's important to note that these are preliminary estimates, subject to finalization of financial closing procedures, and actual results could differ. The company also highlighted that acquired IPR&D charges are inherently unpredictable and not typically forecasted.
Key Highlights
- 1Anticipated $102 million pre-tax acquired IPR&D charge for Q1 2026.
- 2Charge primarily relates to equity securities and collaboration/licensing agreement payments.
- 3Expected negative impact of $0.81 per diluted share on both GAAP and non-GAAP net income for Q1 2026.
- 4Preliminary financial information; actual results may vary.
- 5Acquired IPR&D charges are unpredictable and not forecasted by the company.
- 6The company provides context on its use of non-GAAP financial measures.